246 related articles for article (PubMed ID: 37258273)
1. Determinants of adherence to daily PrEP measured as intracellular tenofovir diphosphate concentrations over 24 months of follow-up among men who have sex with men.
van den Elshout MA; Hoornenborg E; Coyer L; Anderson PL; Davidovich U; de Vries HJ; Prins M; Schim van der Loeff MF;
Sex Transm Infect; 2023 Aug; 99(5):303-310. PubMed ID: 37258273
[TBL] [Abstract][Full Text] [Related]
2. Adherence to event-driven HIV PrEP among men who have sex with men in Amsterdam, the Netherlands: analysis based on online diary data, 3-monthly questionnaires and intracellular TFV-DP.
Jongen VW; Hoornenborg E; van den Elshout MA; Boyd A; Zimmermann HM; Coyer L; Davidovich U; Anderson PL; de Vries HJ; Prins M; Schim van der Loeff MF;
J Int AIDS Soc; 2021 May; 24(5):e25708. PubMed ID: 33973373
[TBL] [Abstract][Full Text] [Related]
3. High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.
Hoagland B; Moreira RI; De Boni RB; Kallas EG; Madruga JV; Vasconcelos R; Goulart S; Torres TS; Marins LMS; Anderson PL; Luz PM; Costa Leite ID; Liu AY; Veloso VG; Grinsztejn B;
J Int AIDS Soc; 2017 Apr; 20(1):21472. PubMed ID: 28418232
[TBL] [Abstract][Full Text] [Related]
4. Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial.
Songtaweesin WN; Kawichai S; Phanuphak N; Cressey TR; Wongharn P; Saisaengjan C; Chinbunchorn T; Janyam S; Linjongrat D; Puthanakit T;
J Int AIDS Soc; 2020 Sep; 23 Suppl 5(Suppl 5):e25564. PubMed ID: 32869511
[TBL] [Abstract][Full Text] [Related]
5. Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial.
Goldwirt L; Bauer R; Liegeon G; Charreau I; Delaugerre C; Cotte L; Pialou G; Cua E; Laghzal A; Buschman L; Anderson PL; Mourah S; Meyer L; Molina JM;
J Antimicrob Chemother; 2021 Sep; 76(10):2675-2680. PubMed ID: 34278433
[TBL] [Abstract][Full Text] [Related]
6. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.
Anderson PL; Liu AY; Castillo-Mancilla JR; Gardner EM; Seifert SM; McHugh C; Wagner T; Campbell K; Morrow M; Ibrahim M; Buchbinder S; Bushman LR; Kiser JJ; MaWhinney S
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038282
[TBL] [Abstract][Full Text] [Related]
7. Improving adherence to daily preexposure prophylaxis among MSM in Amsterdam by providing feedback via a mobile application.
van den Elshout MAM; Hoornenborg E; Achterbergh RCA; Coyer L; Anderson PL; Davidovich U; de Vries HJC; Prins M; van der Loeff MFS;
AIDS; 2021 Sep; 35(11):1823-1834. PubMed ID: 34001705
[TBL] [Abstract][Full Text] [Related]
8. Concordance between daily diary reported pre-exposure prophylaxis intake and intraerythrocytic tenofovir diphosphate in the Amsterdam Pre-exposure Prophylaxis demonstration project.
Wijstma ES; Jongen VW; Boyd A; van den Elshout MAM; de Vries HJC; Davidovich U; Anderson PL; Prins M; Hoornenborg E; Schim van der Loeff MF
AIDS; 2024 Jul; 38(8):1248-1256. PubMed ID: 38518076
[TBL] [Abstract][Full Text] [Related]
9. High PrEP uptake and objective longitudinal adherence among HIV-exposed women with personal or partner plans for pregnancy in rural Uganda: A cohort study.
Matthews LT; Atukunda EC; Owembabazi M; Kalyebera KP; Psaros C; Chitneni P; Hendrix CW; Marzinke MA; Anderson PL; Isehunwa OO; Hurwitz KE; Bennett K; Muyindike W; Bangsberg DR; Haberer JE; Marrazzo JM; Bwana MB
PLoS Med; 2023 Feb; 20(2):e1004088. PubMed ID: 36795763
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa.
Stranix-Chibanda L; Anderson PL; Kacanek D; Hosek S; Huang S; Nematadzira TG; Taulo F; Korutaro V; Nakabiito C; Masenya M; Lypen K; Brown E; Ibrahim ME; Yager J; Wiesner L; Johnston B; Amico KR; Rooney JF; Chakhtoura N; Spiegel HML; Chi BH;
Clin Infect Dis; 2021 Oct; 73(7):e1893-e1900. PubMed ID: 33341883
[TBL] [Abstract][Full Text] [Related]
11. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial.
Celum C; Hosek S; Tsholwana M; Kassim S; Mukaka S; Dye BJ; Pathak S; Mgodi N; Bekker LG; Donnell DJ; Wilson E; Yuha K; Anderson PL; Agyei Y; Noble H; Rose SM; Baeten JM; Fogel JM; Adeyeye A; Wiesner L; Rooney J; Delany-Moretlwe S
PLoS Med; 2021 Jun; 18(6):e1003670. PubMed ID: 34143779
[TBL] [Abstract][Full Text] [Related]
12. Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis.
Ibrahim ME; Castillo-Mancilla JR; Yager J; Brooks KM; Bushman L; Saba L; Kiser JJ; MaWhinney S; Anderson PL
AIDS Res Hum Retroviruses; 2021 Jun; 37(6):421-428. PubMed ID: 33191774
[TBL] [Abstract][Full Text] [Related]
13. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
[TBL] [Abstract][Full Text] [Related]
14. Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial.
Celum CL; Gill K; Morton JF; Stein G; Myers L; Thomas KK; McConnell M; van der Straten A; Baeten JM; Duyver M; Mendel E; Naidoo K; Dallimore J; Wiesner L; Bekker LG
J Int AIDS Soc; 2020 Nov; 23(11):e25636. PubMed ID: 33247553
[TBL] [Abstract][Full Text] [Related]
15. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.
Glidden DV; Das M; Dunn DT; Ebrahimi R; Zhao Y; Stirrup OT; Baeten JM; Anderson PL
J Int AIDS Soc; 2021 May; 24(5):e25744. PubMed ID: 34021709
[TBL] [Abstract][Full Text] [Related]
16. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
Yager J; Castillo-Mancilla J; Ibrahim ME; Brooks KM; McHugh C; Morrow M; McCallister S; Bushman LR; MaWhinney S; Kiser JJ; Anderson PL
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):323-330. PubMed ID: 32539288
[TBL] [Abstract][Full Text] [Related]
17. "I wish to remain HIV negative": Pre-exposure prophylaxis adherence and persistence in transgender women and men who have sex with men in coastal Kenya.
Kimani M; van der Elst EM; Chirro O; Wahome E; Ibrahim F; Mukuria N; de Wit TFR; Graham SM; Operario D; Sanders EJ
PLoS One; 2021; 16(1):e0244226. PubMed ID: 33465090
[TBL] [Abstract][Full Text] [Related]
18. Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort study.
Tapsoba JD; Cover J; Obong'o C; Brady M; Cressey TR; Mori K; Okomo G; Kariithi E; Obanda R; Oluoch-Madiang D; Chen YQ; Drain P; Duerr A
PLoS Med; 2022 Sep; 19(9):e1004097. PubMed ID: 36095005
[TBL] [Abstract][Full Text] [Related]
19. Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing.
Spinelli MA; Glidden DV; Anderson PL; Gandhi M; Cohen S; Vittinghoff E; Coleman ME; Scott H; Bacon O; Elion R; Kolber MA; Buchbinder SP; Liu AY
J Acquir Immune Defic Syndr; 2019 Jun; 81(2):158-162. PubMed ID: 31095005
[TBL] [Abstract][Full Text] [Related]
20. Effect of HIV Self-Testing on PrEP Adherence Among Gender-Diverse Sex Workers in Uganda: A Randomized Trial.
Mujugira A; Nakyanzi A; Nabaggala MS; Muwonge TR; Ssebuliba T; Bagaya M; Nampewo O; Sapiri O; Nyanzi KR; Bambia F; Nsubuga R; Serwadda DM; Ware NC; Baeten JM; Haberer JE
J Acquir Immune Defic Syndr; 2022 Apr; 89(4):381-389. PubMed ID: 34954718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
